TY - JOUR
T1 - Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons with Human Immunodeficiency Virus
T2 - The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study
AU - Ryom, Lene
AU - Dilling Lundgren, Jens
AU - Reiss, Peter
AU - Kirk, Ole
AU - Law, Matthew
AU - Ross, Mike
AU - Morlat, Phillip
AU - Andreas Fux, Christoph
AU - Fontas, Eric
AU - De Wit, Stephane
AU - D'Arminio Monforte, Antonella
AU - El-Sadr, Wafaa
AU - Phillips, Andrew
AU - Ingrid Hatleberg, Camilla
AU - Sabin, Caroline
AU - Mocroft, Amanda
N1 - Funding Information:
Potential conflicts of interest. P. R. has served as a scientific advisor to BMS, Gilead Sciences, Grupo Ferrer, GlaxoSmithKline, Janssen Pharmaceuticals, Merck, and ViiV Healthcare. He has served on data and safety monitoring boards and end-point adjudication committees for Janssen Pharmaceuticals and his institution has received honoraria for speaking engagements at scientific conferences from BMS, Gilead Sciences, GlaxoSmithKline. He has received research support from Gilead Sciences, ViiV Healthcare, Merck, Janssen Pharmaceuticals, BMS, Abbott, and Boehringer Ingelheim Pharmaceuticals. O. K. had prior/present board membership at ViiV Healthcare, Gilead Sciences and Merck, received payment for lectures and/or for development of educational presentations from Abbott, Gilead Sciences and Tibotec and had travel/accommodations/meeting expenses paid by Abbott, BMS, Gilead Sciences, Merck and ViiV Healthcare. M. L. has received research grants from Boehringer Ingelheim, BMS, Gilead, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme, Pfizer and Roche. P. M. has received honorarium and support for travel to meeting from Gilead Sciences, ViiV Healthcare and Merck. C. A. F. is an advisory board member for Gilead Sciences and MSD, has pending grants from Gilead Sciences and Abbott and received payment for lectures by Gilead HIV and the body. A. d. M. has past board membership at AbbVie, BMS, Gilead Sciences, Janssen Pharmaceuticals and Merck. A. P. received personal fees from Gilead Sciences, AbbVie, GlaxoSmithKline Vaccines and grants from BMS. C. S. received personal fees from Gilead Sciences, BMS, Janssen Pharmaceuticals, Abbott Pharmaceuticals, and ViiV Healthcare. A. M. has received consultancy fees/honoraria/ speaker fees from BMS, Pfizer, Merck, Boehringer Ingelheim, and Gilead Sciences. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Funding Information:
Financial support. The D:A:D study was supported by the Highly Active Antiretroviral Therapy Oversight Committee, a collaborative committee with representation from academic institutions, the European Agency for the Evaluation of Medicinal Products, the US Food and Drug Administration, the patient community, and pharmaceutical companies with licensed anti-HIV drugs in the European Union: AbbVie, Bristol-Myers Squibb (BMS), Gilead Sciences, ViiV Healthcare, Merck, and Janssen Pharmaceuticals. It was also supported also by the Danish National Research Foundation (CHIP and PERSIMUNE) (grant DNRF126), the Dutch Ministry of Health, Welfare and Sport through the Center for Infectious Disease Control of the National Institute for Public Health and the Environment to Stiching HIV Monitoring (to ATHENA), and the Agence Nationale de Recherches sur le Sida et les Hépatites Virales (Action Coordonnée 7 [Cohortes] to the Aquitaine Cohort). AHOD is funded as part of the Asia Pacific HIV Observational Database, a program of The Foundation for AIDS Research, and is supported in part by the US National Institutes of Health’s National Institute of Allergy and Infectious Diseases (grant U01-AI069907) and by unconditional grants from Merck Sharp & Dohme, Gilead Sciences, BMS, Boehringer Ingelheim, Janssen-Cilag, and ViiV Healthcare. The Kirby Institute is funded by the Australian Government Department of Health and Ageing and is affiliated with the Faculty of Medicine, The University of New South Wales. BASS is supported by the Fondo de Investigación Sanitaria (grant FIS 99/0887) and Fundación Para la Investigación y la Prevención del SIDA en Espanã (grant FIPSE 3171/00). The CPCRA is supported by the National Institute of Allergy and Infectious Diseases, National Institutes of Health (grants 5U01AI042170-10 and 5U01AI046362-03). Primary funding is provided by the European Union’s Seventh Framework Programme for research, technological development, and demonstration (under EuroCoord grant 260694) and by unrestricted grants by BMS, Janssen Research & Development, Merck, Pfizer., and GlaxoSmithKline. The participation of centers from Switzerland is supported by the Swiss National Science Foundation (grant 108787 to the EuroSIDA study). The ICONA Foundation is supported by unrestricted educational grants from AbbVie, BMS, Gilead Sciences, GlaxoSmithKline, Pfizer, and Janssen Pharmaceuticals. The SHCS is supported by the Swiss National Science Foundation (grant 148522).
Publisher Copyright:
© 2019 The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
PY - 2019/10/8
Y1 - 2019/10/8
N2 - Background: It is unclear whether use of contemporary protease inhibitors pose a similar risk of chronic kidney disease (CKD) as use of older protease inhibitors. Methods: Participants in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study were followed up until the earliest occurrence of CKD, the last visit plus 6 months, or 1 February 2016. Adjusted Poisson regression was used to assess associations between CKD and the use of ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted darunavir (DRV/r). Results: The incidence of CKD (10.0/1000 person-years of follow-up; 95% confidence interval, 9.5-10.4/1000 person-years of follow-up) increased gradually with increasing exposure to ATV/r, but the relation was less clear for DRV/r. After adjustment, only exposure to ATV/r (adjusted incidence rate ratio, 1.4; 95% confidence interval, 1.2-1.6), but not exposure to DRV/r (1.0;. 8-1.3), remained significantly associated with CKD. Conclusion: While DRV/r use was not significantly associated with CKD an increasing incidence with longer ATV/r use was confirmed.
AB - Background: It is unclear whether use of contemporary protease inhibitors pose a similar risk of chronic kidney disease (CKD) as use of older protease inhibitors. Methods: Participants in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study were followed up until the earliest occurrence of CKD, the last visit plus 6 months, or 1 February 2016. Adjusted Poisson regression was used to assess associations between CKD and the use of ritonavir-boosted atazanavir (ATV/r) or ritonavir-boosted darunavir (DRV/r). Results: The incidence of CKD (10.0/1000 person-years of follow-up; 95% confidence interval, 9.5-10.4/1000 person-years of follow-up) increased gradually with increasing exposure to ATV/r, but the relation was less clear for DRV/r. After adjustment, only exposure to ATV/r (adjusted incidence rate ratio, 1.4; 95% confidence interval, 1.2-1.6), but not exposure to DRV/r (1.0;. 8-1.3), remained significantly associated with CKD. Conclusion: While DRV/r use was not significantly associated with CKD an increasing incidence with longer ATV/r use was confirmed.
KW - CKD
KW - HIV
KW - adverse drug effect
KW - atazanavir
KW - darunavir
KW - nephrotoxicity
KW - protease inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85073088603&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85073088603&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiz369
DO - 10.1093/infdis/jiz369
M3 - Article
C2 - 31504669
AN - SCOPUS:85073088603
VL - 220
SP - 1629
EP - 1634
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
SN - 0022-1899
IS - 10
ER -
